Cizutamig

Phase 1Small molecule

CCandid Therapeutics

Cizutamig is one of 149 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

148

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Myasthenia GravisActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Ulcerative ColitisPhase 1

Active, not recruiting

Myasthenia GravisPhase 1

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Preclinical

47 2

Simponi

Johnson & Johnson

Preclinical

19 3

Enbrel

IImmunex

Preclinical

64 4

Remicade

OOrganon and Co

Preclinical

43 5

Arcoxia

Novartis

Preclinical

4 6

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 7

Ilaris

Novartis

Preclinical

3 8

Celexa

AbbVie

Preclinical

1 9

Kineret

SSwedish Orphan Biovitrum

Preclinical

6 10

Cataflam

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Phase 1

NCT07408869

Q2 2027

Phase 1Recruiting

Rheumatoid Arthritis

NCT06946199

Q4 2027

Phase 1Not yet recruiting

Ulcerative Colitis

NCT07353450

Q2 2028

Phase 1Recruiting

Systemic Lupus Erythematosus

NCT07215663

Phase 1Recruiting

Myasthenia Gravis

NCT07215650

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

A Study of Cizutamig for Patients With Ulcerative Colitis

Not yet recruiting·RRuijin Hospital·Phase 1·NCT07353450·15 enrolled

Systemic Lupus Erythematosus1 trial

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

Recruiting·CCandid Therapeutics·Phase 1·NCT07215663·47 enrolled

Adult1 trial

Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants

Recruiting·CCandid Therapeutics·Phase 1·NCT07236411·20 enrolled

Rheumatoid Arthritis1 trial

An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT06946199·28 enrolled

Phase 11 trial

A Phase 1 Study of Cizutamig in IgE Mediated Diseases

Not yet recruiting·CCandid Therapeutics·Phase 1·NCT07408869·20 enrolled

1 more indication

Myasthenia Gravis1 trial

Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

Recruiting·CCandid Therapeutics·Phase 1·NCT07215650·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Cizutamig. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cizutamig compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cizutamig. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Candid Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCandid Therapeutics

Cizutamig

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Ulcerative Colitis1 trial

Systemic Lupus Erythematosus1 trial

Adult1 trial

Rheumatoid Arthritis1 trial

Phase 11 trial

Myasthenia Gravis1 trial

References

Drug Info

Quick Facts

Related News